Lexicon Pharmaceuticals | LXRX - Bénéfice Avant Impôts





Bénéfice Avant Impôts Changement Date
Abbott USD 2.39B 27M 2026-03
Acadia Pharmaceuticals USD 46.47M 42.49M 2026-06
Agios Pharmaceuticals USD -99.11M 9.94M 2026-03
Akebia Therapeutics USD -11.24M 12.39M 2025-12
Alnylam Pharmaceuticals USD 177.81M 43.85M 2026-06
AstraZeneca USD 4.81B 894M 2026-06
BioMarin Pharmaceutical USD 141.2M 168.36M 2026-03
Coherus Biosciences USD -46.35M 90.86M 2025-12
Eli Lilly USD 8.85B 583.8M 2026-03
Halozyme Therapeutics USD 180.33M 281.18M 2026-03
Illumina USD 260M 103M 2026-06
Insmed USD -11.37M 150.72M 2026-06
Ironwood Pharmaceuticals USD 68.02M 30.2M 2025-09
J&J USD 8.66B 839M 2026-06
Lexicon Pharmaceuticals USD -12.77M 16.02M 2025-09
MacroGenics USD -36.77M 21.84M 2026-03
MannKind USD -16.37M 4.56M 2026-03
Merck USD -3.53B 6.95B 2026-03
Moderna USD -1.33B 535M 2026-03
Novartis USD 4.27B 430M 2026-06
PTC Therapeutics USD -2.46M 136.62M 2026-03
Puma Biotechnology USD 20.61M 24.76M 2024-09
Sarepta Therapeutics USD -1.75M 344.92M 2026-06
Thermo Fisher Scientific USD 1.73B 389M 2026-03
Ultragenyx Pharmaceutical USD -91M 93M 2026-06
United Therapeutics USD 372.7M 54.4M 2026-06
Vanda Pharmaceuticals USD -22.92M 16.68M 2024-12